KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $2.5 million.

  • AbCellera Biologics' Gains from Investment Securities fell 9022.22% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.3 million, marking a year-over-year decrease of 12360.85%. This contributed to the annual value of $19.7 million for FY2024, which is 4395.91% up from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Gains from Investment Securities is $2.5 million, which was down 9022.22% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Gains from Investment Securities peaked at $25.1 million during Q3 2024, and registered a low of -$16.2 million during Q4 2024.
  • Its 5-year average for Gains from Investment Securities is $5.1 million, with a median of $4.5 million in 2023.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 4345357.14% in 2021, then crashed by 56544.88% in 2024.
  • Quarter analysis of 5 years shows AbCellera Biologics' Gains from Investment Securities stood at $3.2 million in 2021, then soared by 83.62% to $5.9 million in 2022, then crashed by 41.17% to $3.5 million in 2023, then plummeted by 565.45% to -$16.2 million in 2024, then soared by 115.15% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.6 million for Q2 2025, and $1.9 million during Q1 2025.